HK1215049A1 - 化學交聯劑 - Google Patents
化學交聯劑Info
- Publication number
- HK1215049A1 HK1215049A1 HK16102953.3A HK16102953A HK1215049A1 HK 1215049 A1 HK1215049 A1 HK 1215049A1 HK 16102953 A HK16102953 A HK 16102953A HK 1215049 A1 HK1215049 A1 HK 1215049A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- chemical crosslinkers
- crosslinkers
- chemical
- Prior art date
Links
- 239000004971 Cross linker Substances 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361794784P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/027818 WO2014143734A2 (en) | 2013-03-15 | 2014-03-14 | Chemical crosslinkers |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1215049A1 true HK1215049A1 (zh) | 2016-08-12 |
Family
ID=51537517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16102953.3A HK1215049A1 (zh) | 2013-03-15 | 2016-03-15 | 化學交聯劑 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9889203B2 (zh) |
EP (2) | EP3714893A1 (zh) |
JP (2) | JP6506250B2 (zh) |
KR (1) | KR20150132126A (zh) |
CN (1) | CN105189742A (zh) |
AU (2) | AU2014228231B2 (zh) |
BR (1) | BR112015022780A2 (zh) |
CA (1) | CA2902210C (zh) |
ES (1) | ES2804594T3 (zh) |
HK (1) | HK1215049A1 (zh) |
IL (1) | IL240209A0 (zh) |
MX (1) | MX2015012873A (zh) |
SG (1) | SG11201505936QA (zh) |
WO (2) | WO2014143701A1 (zh) |
ZA (1) | ZA201506363B (zh) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014143701A1 (en) * | 2013-03-15 | 2014-09-18 | Amicus Therapeutics, Inc. | Chemical crosslinkers |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
KR101847536B1 (ko) * | 2015-06-02 | 2018-04-11 | 한국생명공학연구원 | 효모 세포벽 만노단백질 유래의 당사슬을 이용한 만노스-6-인산 당사슬이 부가된 당단백질의 제조방법 |
CA3098674A1 (en) | 2018-04-30 | 2019-11-07 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
WO2020077114A2 (en) | 2018-10-10 | 2020-04-16 | Amicus Therapeutics, Inc. | Disulfide bond stabilized polypeptide compositions and methods of use |
WO2021072372A1 (en) * | 2019-10-10 | 2021-04-15 | Amicus Therapeutics, Inc. | Variant igf2 constructs |
TW202237850A (zh) | 2020-12-01 | 2022-10-01 | 賓州大學委員會 | 具有組織特異性靶向基序的新穎構成物及含有其之組成物 |
US20240207452A1 (en) | 2021-04-23 | 2024-06-27 | The Trustees Of The University Of Pennsylvania | Novel compositions with brain-specific targeting motifs and compositions containing same |
WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
CA2723664A1 (en) * | 2000-03-22 | 2001-09-27 | Solulink, Incorporated | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
PL1877099T3 (pl) * | 2005-04-06 | 2013-02-28 | Genzyme Corp | Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą |
JP5628476B2 (ja) * | 2005-04-28 | 2014-11-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 抗体コンジュゲート |
WO2008011157A2 (en) * | 2006-07-20 | 2008-01-24 | The General Hospital Corporation | Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting |
CN102781965A (zh) * | 2009-10-06 | 2012-11-14 | 安吉奥开米公司 | 用于转运治疗剂的组合物和方法 |
CN108586621A (zh) * | 2011-05-27 | 2018-09-28 | 阿米库斯治疗学公司 | 将靶向肽偶联于重组溶酶体酶上的方法 |
US20150037311A1 (en) * | 2011-12-01 | 2015-02-05 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
WO2014143701A1 (en) * | 2013-03-15 | 2014-09-18 | Amicus Therapeutics, Inc. | Chemical crosslinkers |
-
2014
- 2014-03-14 WO PCT/US2014/027771 patent/WO2014143701A1/en active Application Filing
- 2014-03-14 EP EP20170446.7A patent/EP3714893A1/en not_active Withdrawn
- 2014-03-14 CA CA2902210A patent/CA2902210C/en active Active
- 2014-03-14 AU AU2014228231A patent/AU2014228231B2/en active Active
- 2014-03-14 WO PCT/US2014/027818 patent/WO2014143734A2/en active Application Filing
- 2014-03-14 KR KR1020157023763A patent/KR20150132126A/ko not_active Application Discontinuation
- 2014-03-14 CN CN201480008669.3A patent/CN105189742A/zh active Pending
- 2014-03-14 US US14/762,647 patent/US9889203B2/en active Active
- 2014-03-14 MX MX2015012873A patent/MX2015012873A/es unknown
- 2014-03-14 JP JP2016502634A patent/JP6506250B2/ja active Active
- 2014-03-14 ES ES14764160T patent/ES2804594T3/es active Active
- 2014-03-14 EP EP14764160.9A patent/EP2976092B1/en active Active
- 2014-03-14 SG SG11201505936QA patent/SG11201505936QA/en unknown
- 2014-03-14 BR BR112015022780A patent/BR112015022780A2/pt not_active Application Discontinuation
-
2015
- 2015-07-29 IL IL240209A patent/IL240209A0/en unknown
- 2015-08-31 ZA ZA2015/06363A patent/ZA201506363B/en unknown
-
2016
- 2016-03-15 HK HK16102953.3A patent/HK1215049A1/zh unknown
-
2018
- 2018-02-08 US US15/891,397 patent/US10814008B2/en active Active
-
2019
- 2019-03-28 JP JP2019063679A patent/JP2019142889A/ja active Pending
- 2019-05-16 AU AU2019203437A patent/AU2019203437A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL240209A0 (en) | 2015-09-24 |
AU2014228231B2 (en) | 2019-02-21 |
JP2019142889A (ja) | 2019-08-29 |
BR112015022780A2 (pt) | 2018-02-06 |
US9889203B2 (en) | 2018-02-13 |
ZA201506363B (en) | 2017-11-29 |
ES2804594T3 (es) | 2021-02-08 |
US10814008B2 (en) | 2020-10-27 |
EP2976092B1 (en) | 2020-04-22 |
CA2902210C (en) | 2021-07-20 |
AU2019203437A1 (en) | 2019-06-13 |
SG11201505936QA (en) | 2015-09-29 |
MX2015012873A (es) | 2016-02-03 |
EP2976092A2 (en) | 2016-01-27 |
KR20150132126A (ko) | 2015-11-25 |
WO2014143701A1 (en) | 2014-09-18 |
CA2902210A1 (en) | 2014-09-18 |
US20180185503A1 (en) | 2018-07-05 |
CN105189742A (zh) | 2015-12-23 |
WO2014143734A2 (en) | 2014-09-18 |
JP6506250B2 (ja) | 2019-04-24 |
EP2976092A4 (en) | 2016-11-23 |
AU2014228231A1 (en) | 2015-08-13 |
WO2014143734A3 (en) | 2014-12-04 |
JP2016515510A (ja) | 2016-05-30 |
US20160129126A1 (en) | 2016-05-12 |
EP3714893A1 (en) | 2020-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180839T1 (hr) | Kemijske vrste | |
HK1222859A1 (zh) | 化合物 | |
AU355447S (en) | Case | |
AU354443S (en) | Case | |
AU354395S (en) | Case | |
GB201304245D0 (en) | Chemical compounds | |
HK1214592A1 (zh) | 化合物 | |
HK1215049A1 (zh) | 化學交聯劑 | |
GB201316824D0 (en) | New Chemical Entities | |
GB201518344D0 (en) | No details present | |
GB201421649D0 (en) | No details | |
GB201408089D0 (en) | No details | |
GB201416327D0 (en) | No details | |
GB201316823D0 (en) | New Chemical Entities | |
GB201407200D0 (en) | No details | |
GB201310928D0 (en) | New Processes | |
GB201322733D0 (en) | Chemical compounds | |
GB201313885D0 (en) | Chemical Compounds | |
GB201306881D0 (en) | Chemical compounds | |
GB201323054D0 (en) | No details | |
GB201323056D0 (en) | No details | |
GB201323055D0 (en) | No details | |
AU352702S (en) | Door clip | |
GB201318565D0 (en) | New processes | |
GB201307978D0 (en) | No details |